• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国经典型和迟发性 Fabry 病患者不同性别和年龄的首发表现和肾脏受累的演变。

The evolution of the initial manifestations and renal involvement of chinese patients with classical and late-onset Fabry disease at different sexes and ages.

机构信息

School of Medicine, Nankai University, Tianjin, China.

Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Chinese PLA Institute of Nephrology, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing, China.

出版信息

BMC Nephrol. 2023 Apr 5;24(1):90. doi: 10.1186/s12882-023-03138-w.

DOI:10.1186/s12882-023-03138-w
PMID:37020293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10074707/
Abstract

BACKGROUND

Fabry disease is a rare hereditary disease involving multiple organs, and there are few reports on how the initial manifestations and renal involvement of these patients with classical and late-onset phenotype evolve with sexes and ages. To improve clinicians' understanding of Fabry disease and avoid misdiagnoses by discussing the initial manifestations, first medical specialties visited and renal involvement development in patients.

METHODS

This study collected relevant data from 311 Chinese Fabry disease patients (200 males, 111 females) and descriptive statistical analysis was used to analyze the evolution of the initial manifestations and renal involvement of patients with classical and late-onset phenotype at different sexes and ages.

RESULTS

Regarding the age at manifestation onset, age at the first medical specialty visited and age at the diagnosis of Fabry disease, males were earlier than females, and males with classical phenotype were earlier than males with late-onset and females with classical phenotype. In both male and female patients, the initial manifestations of classical patients were mainly acroparesthesia, and the first medical specialty visited were mainly pediatrics and neurology. The initial manifestations of late-onset patients were mainly renal and cardiovascular involvement, and the first medical specialty visited were mainly nephrology and cardiology. In classical patients, both male and female, the initial manifestations of the preschool and the juvenile groups were mainly acroparesthesia, and the frequency of renal and cardiovascular involvement in the young group was higher than that in the preschool and juvenile groups. There was no obvious renal involvement in the preschool group, renal involvement was most common in the young group and the middle-aged and elderly group. Proteinuria can appear in classical male patients as early as approximately 20 years, and renal insufficiency can occur at approximately 25 years. With age, over 50% of classical male patients can develop varying degrees of proteinuria at the age of 25 and renal insufficiency at the age of 40. 15.94% of the patients progressed to dialysis or kidney transplantation, mainly classical males.

CONCLUSIONS

The initial manifestation of Fabry disease is affected by sex, age and classical/late-onset phenotype. The initial manifestations were mainly acroparesthesia and the frequency and degree of renal involvement increased gradually with aging in classical male patients.

摘要

背景

法布瑞病是一种累及多器官的罕见遗传性疾病,目前有关经典型和晚发型表型患者的首发表现及肾脏受累随性别和年龄变化的报道较少。为提高临床医生对法布瑞病的认识,避免误诊,通过讨论患者的首发表现、首诊科室及肾脏受累进展情况。

方法

本研究收集了 311 例中国法布瑞病患者(男性 200 例,女性 111 例)的相关数据,采用描述性统计分析方法,分析不同性别和年龄的经典型和晚发型表型患者首发表现及肾脏受累的演变。

结果

在发病年龄、首诊年龄、确诊年龄方面,男性早于女性,经典型男性早于晚发型男性和经典型女性;男女患者中,经典型患者首发表现主要为肢端感觉异常,首诊科室主要为儿科和神经内科;晚发型患者首发表现主要为肾脏和心血管受累,首诊科室主要为肾内科和心内科;经典型患者中,学龄前和青少年组男女患者首发表现均主要为肢端感觉异常,青年组肾脏和心血管受累发生率高于学龄前和青少年组;学龄前组无明显肾脏受累,青年组和中老年组肾脏受累最常见;经典型男性患者蛋白尿最早可出现在 20 岁左右,肾功能不全可出现在 25 岁左右,随着年龄的增长,25 岁时超过 50%的经典型男性患者可出现不同程度的蛋白尿,40 岁时出现肾功能不全;有 15.94%的患者进展为透析或肾移植,主要为经典型男性。

结论

法布瑞病的首发表现受性别、年龄和经典/晚发型表型的影响,经典型男性患者的首发表现主要为肢端感觉异常,且随着年龄的增长,肾脏受累的频率和程度逐渐增加。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3592/10074707/1900f72af995/12882_2023_3138_Figa_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3592/10074707/1900f72af995/12882_2023_3138_Figa_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3592/10074707/1900f72af995/12882_2023_3138_Figa_HTML.jpg

相似文献

1
The evolution of the initial manifestations and renal involvement of chinese patients with classical and late-onset Fabry disease at different sexes and ages.中国经典型和迟发性 Fabry 病患者不同性别和年龄的首发表现和肾脏受累的演变。
BMC Nephrol. 2023 Apr 5;24(1):90. doi: 10.1186/s12882-023-03138-w.
2
Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.通过全国性调查对韩国法布里病患者中GLA的临床特征和突变谱进行研究:迟发型表型的诊断不足
Medicine (Baltimore). 2017 Jul;96(29):e7387. doi: 10.1097/MD.0000000000007387.
3
Musculoskeletal manifestations of Fabry disease: A retrospective study.法布里病的肌肉骨骼表现:一项回顾性研究。
Joint Bone Spine. 2016 Jul;83(4):421-6. doi: 10.1016/j.jbspin.2015.11.001. Epub 2015 Dec 14.
4
[Evaluation of patients with Fabry disease in Argentina].[阿根廷法布里病患者的评估]
Medicina (B Aires). 2010;70(1):37-43.
5
The Prevalence of Fabry Disease in Patients with Chronic Kidney Disease in Turkey: The TURKFAB Study.土耳其慢性肾脏病患者中法布里病的患病率:TURKFAB研究。
Kidney Blood Press Res. 2016;41(6):1016-1024. doi: 10.1159/000452605. Epub 2016 Dec 23.
6
Clinical course and pathological findings of two late-onset Fabry hemizygous patients including mulberry cell counts after enzyme replacement therapy.两名迟发性法布里半合子患者的临床病程及病理结果,包括酶替代治疗后的桑葚细胞计数
CEN Case Rep. 2020 Aug;9(3):237-242. doi: 10.1007/s13730-020-00463-z. Epub 2020 Mar 18.
7
When and How to Diagnose Fabry Disease in Clinical Pratice.何时及如何在临床实践中诊断法布瑞氏病。
Am J Med Sci. 2020 Dec;360(6):641-649. doi: 10.1016/j.amjms.2020.07.011. Epub 2020 Jul 10.
8
Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: An analysis from the Fabry Registry.30 岁前接受阿加糖酶β治疗的法布瑞病年轻患者的临床结局:法布瑞登记研究的分析。
Mol Genet Metab. 2023 Feb;138(2):106967. doi: 10.1016/j.ymgme.2022.106967. Epub 2022 Nov 30.
9
Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications.法布里病:一名老年心脏变异型患者的肾脏受累局限于足细胞病变和蛋白尿。病理及治疗意义
Am J Kidney Dis. 2004 Jan;43(1):164-71. doi: 10.1053/j.ajkd.2003.09.022.
10
Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.巴西法布里病患者的风湿性表现发生率较高且诊断延迟。
Adv Rheumatol. 2020 Jan 6;60(1):7. doi: 10.1186/s42358-019-0111-7.

引用本文的文献

1
A phase 4, open-label, multicenter study of the safety and efficacy of agalsidase beta in Chinese patients with Fabry disease.一项关于阿加糖酶β在中国法布里病患者中安全性和有效性的4期开放标签多中心研究。
Orphanet J Rare Dis. 2025 Aug 4;20(1):401. doi: 10.1186/s13023-025-03950-7.
2
Correlation of enzyme activities and genotype with clinical manifestations in Chinese patients of different sexes with classical and late-onset Fabry disease.不同性别中国经典型和晚发型法布里病患者酶活性、基因型与临床表现的相关性
Front Med. 2025 May 13. doi: 10.1007/s11684-025-1131-9.
3
Establishing Treatment Effectiveness in Fabry Disease: Observation-Based Recommendations for Improvement.

本文引用的文献

1
Fabry disease and kidney involvement: starting from childhood to understand the future.法布里病与肾脏受累:从儿童期开始了解未来
Pediatr Nephrol. 2022 Jan;37(1):95-103. doi: 10.1007/s00467-021-05076-x. Epub 2021 Apr 30.
2
Fabry Disease Therapy: State-of-the-Art and Current Challenges.法布里病治疗:最新进展和当前挑战。
Int J Mol Sci. 2020 Dec 28;22(1):206. doi: 10.3390/ijms22010206.
3
Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.巴西法布里病患者的风湿性表现发生率较高且诊断延迟。
建立法布里病的治疗效果:观察性建议以改善疗效。
Int J Mol Sci. 2024 Sep 9;25(17):9752. doi: 10.3390/ijms25179752.
4
Diagnosing Fabry nephropathy: the challenge of multiple kidney disease.诊断法布里肾病:多种肾病的挑战。
BMC Nephrol. 2023 Nov 21;24(1):344. doi: 10.1186/s12882-023-03388-8.
Adv Rheumatol. 2020 Jan 6;60(1):7. doi: 10.1186/s42358-019-0111-7.
4
Enzyme replacement therapy in Fabry disease in Poland: a position statement.波兰法布里病的酶替代疗法:立场声明。
Pol Arch Intern Med. 2020 Jan 31;130(1):91-97. doi: 10.20452/pamw.15117. Epub 2019 Dec 20.
5
Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients.《儿童法布里病诊断、治疗和管理的共识建议》。
Clin Genet. 2019 Aug;96(2):107-117. doi: 10.1111/cge.13546. Epub 2019 Jun 6.
6
European expert consensus statement on therapeutic goals in Fabry disease.欧洲专家共识声明:法布瑞氏病治疗目标。
Mol Genet Metab. 2018 Jul;124(3):189-203. doi: 10.1016/j.ymgme.2018.06.004. Epub 2018 Jun 12.
7
Fabry disease revisited: Management and treatment recommendations for adult patients.重新审视法布里病:成年患者的管理和治疗建议。
Mol Genet Metab. 2018 Apr;123(4):416-427. doi: 10.1016/j.ymgme.2018.02.014. Epub 2018 Feb 28.
8
Ultrastructural deposits appearing as "zebra bodies" in renal biopsy: Fabry disease?- comparative case reports.肾活检中出现“斑马小体”的超微结构沉积物:法布里病?——病例对照报告
BMC Nephrol. 2017 May 12;18(1):157. doi: 10.1186/s12882-017-0571-0.
9
Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.法布瑞病患者的筛查、诊断和管理:“肾脏病:改善全球预后”(KDIGO)争议会议的结论。
Kidney Int. 2017 Feb;91(2):284-293. doi: 10.1016/j.kint.2016.10.004. Epub 2016 Dec 18.
10
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study.经典型和非经典型法布里病的特征:一项多中心研究
J Am Soc Nephrol. 2017 May;28(5):1631-1641. doi: 10.1681/ASN.2016090964. Epub 2016 Dec 15.